Journals / Türk Nöroşirürji Dergsi / 2019 / Cilt: 29 - Sayı: 3

The Classification of Central Nervous System TumorsFrom Past to Date

Santral Sinir Sistemi Tümörlerinin Sınıflaması Geçmişten Güncele

Pages
217–225
Publication Date
2022-11-05
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

A blue book for the new classification is expected to be published by the end of 2020

📌 3 Key Takeaways

🎯
Objective & Hypothesis:The World Health Organization has published four editions of the Classification of Central Nervous System (CNS) Tumors in the years 1979, 1993, 2000, 2007, and the updated 4th edition in 2016.
📊
Key Findings & Data:The group has released 4 updates in the last 2 years.
💡
Conclusion & Impact:A blue book for the new classification is expected to be published by the end of 2020
🔬Design:Research Article
📍Scope:2000 Verileri
⚙️Variables:Domain Parameters

Abstract

The World Health Organization has published four editions of the Classification of Central Nervous System (CNS) Tumors in the years 1979, 1993, 2000, 2007, and the updated 4th edition in 2016. However, the knowledge on brain tumors is being renewed almost every day. The International Society of Neuropathology (ISN) has decided to publish some guidelines for the current neuropathology practice until a new blue book comes out and has announced cIMPACT-NOW (the Consortium to Inform Molecular and Practical Approaches to CNS Tumor Taxonomy). The group has released 4 updates in the last 2 years. As the cIMPACT-NOW updates were published, the number of molecular tests required for CNS tumors has increased rapidly. It is not possible to disregard these suggestions as in case of a tumor with low-grade morphology, recurrence and mortality could be seen in a very short time and the pathological diagnosis was far from explaining the condition. Following the updates closely, putting them into practice, and taking the recommendations into consideration have made a great contribution to clinicopathological compliance. The first round has been completed, and working groups are now preparing the second round. A blue book for the new classification is expected to be published by the end of 2020

Özet

Dünya Sağlık Örgütü Santral Sinir Sistemi Tümörlerinin Sınıflaması üzerine 1979, 1993, 2000 ve 2007 yılları dahil olmak üzere 4 ayrıedisyon, 2016 yılında ise güncellenmiş 4. edisyonu yayınlamıştı. Ancak bilgiler her geçen gün yenileniyor, bazı doğru kabul edilenleryeni bilgilerle geçerliliğini yitiriyordu. Yeni bir mavi kitap basılana dek Uluslararası Nöropatoloji Topluluğu (ISN), bazı yenilikleri güncelnöropatoloji pratiğinde kullanmaya rehberlik edecek makaleler halinde basıp yayınlamaya karar verdi. ISN tarafından duyurulancIMPACT-NOW (The Consortium to Inform Molecular and Practical Approaches to CNS Tumor Taxonomy) bir sonraki mavi kitapbasılana dek nöropatolog, nöroonkolog ve nöroşirürjiyenlere yol gösterecekti. Grubun 2018’de 3 ve 2019’da 1 güncellemesiyayınlandı. cIMPACT-NOW güncellemeleri yayınlandıkça santral sinir sistemi tümörlerinde uygulanması gereken moleküler testsayısı hızla artıyordu. Bu önerileri dikkate almamak ise mümkün değildi. Zira morfolojiye dayalı olarak düşük dereceli tümör tanısıverilen, bu tanıya dayalı tedavi ve takip planı oluşturulan bir olguda çok kısa sürede nüks ve mortalite görülebilmekte ve patolojik tanıbu durumu açıklamaktan uzak kalmaktaydı. Dolayısıyla güncellemeleri yakından takip etmek, önerileri dikkate alarak uygulamayakoymak klinikopatolojik uyuma büyük katkı sağlamaktaydı. Birinci turu tamamlanan seride şimdi çalışma grupları 2. tur üzerinehazırlıklarını sürdürmekteler. Tahminen 2020 sonlarında ise yeni sınıflama mavi kitabının basılması bekleniyor.

🔖

Cite This Article

DANYELİ, A. E. (2022). The Classification of Central Nervous System TumorsFrom Past to Date. Türk Nöroşirürji Dergsi, Cilt: 29 - Sayı: 3, 217–225. https://ajindex.com/articles/637292

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (1)

  1. Aibaidula A, Chan AK, Shi Z, Li Y, Zhang R, Yang R, Li KK, Chung NY, Yao Y, Zhou L, Wu J, Chen H, Ng HK: Adult IDH wild-type lower-grade gliomas should be further stratified. Neuro Oncol 19(10):1327-1337, 2017 2. Anonymous. EXPERT committee on health statistics. World Health Organ Tech Rep Ser 53:1– 54, 1952 3. Arita H, Yamasaki K, Matsushita Y, Nakamura T, Shimokawa A, Takami H, Tanaka S, Mukasa A, Shirahata M, Shimizu S, Suzuki K, Saito K, Kobayashi K, Higuchi F, Uzuka T, Otani R, Tamura K, Sumita K, Ohno M, Miyakita Y, Kagawa N, Hashimoto N, Hatae R, Yoshimoto K, Shinojima N, Nakamura H, Kanemura Y, Okita Y, Kinoshita M, Ishibashi K, Shofuda T, Kodama Y, Mori K, Tomogane Y, Fukai J, Fujita K, Terakawa Y, Tsuyuguchi N, Moriuchi S, Nonaka M, Suzuki H, Shibuya M, Maehara T, Saito N, Nagane M, Kawahara N, Ueki K, Yoshimine T, Miyaoka E, Nishikawa R, Komori T, Narita Y, Ichimura K: A combination of TERT promoter mutation and MGMT methylation status predicts clinically relevant subgroups of newly diagnosed glioblastomas. Acta Neuropathol Commun 4(1):79, 2016 4. Brat DJ, Aldape K, Colman H, Holland EC, Louis DN, Jenkins RB, Kleinschmidt-DeMasters BK, Perry A, Reifenberger G, Stupp R, von Deimling A, Weller M: cIMPACT-NOW update 3: recommended diagnostic criteria for “Diffuse astrocytic glioma, IDH-wildtype, with molecular features of glioblastoma, WHO grade IV”. Acta Neuropathol 136(5):805-810, 2018 5. Daumas-Duport C, Scheithauer B, O’Fallon J, Kelly P: Grading of astrocytomas. A simple and reproducible method. Cancer 62(10):2152-265, 1988 6. Ellison DW, Hawkins C, Jones DTW, Onar-Thomas A, Pfister SM, Reifenberger G, Louis DN: cIMPACT-NOW update 4: diffuse gliomas characterized by MYB, MYBL1, orFGFR1 alterations or BRAF(V600E) mutation. Acta Neuropathol 137(4):683-687, 2019 7. Gessi M, Capper D, Sahm F, Huang K, von Deimling A, Tippelt S, Fleischhack G, Scherbaum D, Alfer J, Juhnke BO, von Hoff K, Rutkowski S, Warmuth-Metz M, Chavez L, Pfister SM, Pietsch T, Jones DT, Sturm D: Evidence of H3 K27M mutations in posterior fossa ependymomas. Acta Neuropathol 132(4):635-637, 2016 8. Hartmann C, Hentschel B, Wick W, Capper D, Felsberg J, Simon M, Westphal M, Schackert G, Meyermann R, Pietsch T, Reifenberger G, Weller M, Loeffler M, von Deimling A: Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: Implications for cla